<?xml version="1.0" encoding="UTF-8"?>
<p>The third major driver for the success of mAbs has been commercial. Many mAbs have been developed in oncology. The most recent success story is the development of the checkpoint inhibitors against targets such as programmed death ligand 1 (PD-L1) and related targets [
 <xref rid="pntd.0007860.ref011" ref-type="bibr">11</xref>]. The dramatic clinical effect in subgroups of otherwise treatment-refractory cancer patients has led to products with prices well in excess of US$10,000 per month [
 <xref rid="pntd.0007860.ref012" ref-type="bibr">12</xref>]. Another recent milestone for an infectious disease was the global approval of ibalizumab, a humanized mAb that targets CD4 (cluster of differentiation 4) for the second-line treatment of HIV-1 infection [
 <xref rid="pntd.0007860.ref013" ref-type="bibr">13</xref>].
</p>
